Darolutamide in hormone-sensitive and castration-resistant prostate cancer

Valeria Emma Palmieri; Giandomenico Roviello; Alberto D'Angelo; Chiara Casadei; Ugo De Giorgi; Roberta Giorgione

doi:10.1080/17512433.2021.1901580

Darolutamide in hormone-sensitive and castration-resistant prostate cancer

Valeria Emma Palmieri, Giandomenico Roviello, Alberto D'Angelo, Chiara Casadei, Ugo De Giorgi, Roberta Giorgione

Department of Life Sciences

Research output: Contribution to journal › Article › peer-review

4 Citations (SciVal)

219 Downloads (Pure)

Abstract

Introduction: Important changes in the treatment of prostate cancer have taken place in recent years. Non-metastatic castration-resistant prostate cancer (nmCRPC) has been clinically delineated. In this setting, three drugs have been approved in high-risk disease: apalutamide, enzalutamide and darolutamide.Areas covered:This manuscript aims to profile darolutamide, its clinical development, pharmacologic properties, efficacy and safety. We presented the results of published clinical studies, but we also investigated ongoing ones.Expert opinion: An indirect comparison with the other two aforementioned drugs emerged. While the clinical efficacy is comparable, the toxicity profile is different for darolutamide, resulting in greater tolerance. We must wait for the results of the trials that study darolutamide in hormone-sensitive disease, both in the metastatic phase and in the localized phase. Clinical experience will also be important to determine ever more personalized treatments for patients.

Original language	English
Pages (from-to)	535-544
Number of pages	10
Journal	Expert Review of Clinical Pharmacology
Volume	14
Issue number	5
Early online date	21 Mar 2021
DOIs	https://doi.org/10.1080/17512433.2021.1901580
Publication status	Published - 31 Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Darolutamide
androgen receptor antagonist
castration-resistant
hormone-sensitive
non-metastatic
prostate cancer

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology (medical)

Access to Document

10.1080/17512433.2021.1901580

Drug_profile_Darolutamide_ADA (2)
This is an Accepted Manuscript of an article published by Taylor & Francis in Expert review of clinical pharmacology on 21/3/2021, available online: https://www.tandfonline.com/doi/abs/10.1080/17512433.2021.1901580?journalCode=ierj20
Accepted author manuscript, 293 KBLicence: CC BY-NC

Cite this

@article{a5f0730b718643498b5ea1e4c654071a,

title = "Darolutamide in hormone-sensitive and castration-resistant prostate cancer",

abstract = "Introduction: Important changes in the treatment of prostate cancer have taken place in recent years. Non-metastatic castration-resistant prostate cancer (nmCRPC) has been clinically delineated. In this setting, three drugs have been approved in high-risk disease: apalutamide, enzalutamide and darolutamide.Areas covered:This manuscript aims to profile darolutamide, its clinical development, pharmacologic properties, efficacy and safety. We presented the results of published clinical studies, but we also investigated ongoing ones.Expert opinion: An indirect comparison with the other two aforementioned drugs emerged. While the clinical efficacy is comparable, the toxicity profile is different for darolutamide, resulting in greater tolerance. We must wait for the results of the trials that study darolutamide in hormone-sensitive disease, both in the metastatic phase and in the localized phase. Clinical experience will also be important to determine ever more personalized treatments for patients.",

keywords = "Darolutamide, androgen receptor antagonist, castration-resistant, hormone-sensitive, non-metastatic, prostate cancer",

author = "Palmieri, \{Valeria Emma\} and Giandomenico Roviello and Alberto D'Angelo and Chiara Casadei and \{De Giorgi\}, Ugo and Roberta Giorgione",

year = "2021",

month = dec,

day = "31",

doi = "10.1080/17512433.2021.1901580",

language = "English",

volume = "14",

pages = "535--544",

journal = "Expert Review of Clinical Pharmacology",

issn = "1751-2433",

publisher = "Taylor and Francis",

number = "5",

}

TY - JOUR

T1 - Darolutamide in hormone-sensitive and castration-resistant prostate cancer

AU - Palmieri, Valeria Emma

AU - Roviello, Giandomenico

AU - D'Angelo, Alberto

AU - Casadei, Chiara

AU - De Giorgi, Ugo

AU - Giorgione, Roberta

PY - 2021/12/31

Y1 - 2021/12/31

N2 - Introduction: Important changes in the treatment of prostate cancer have taken place in recent years. Non-metastatic castration-resistant prostate cancer (nmCRPC) has been clinically delineated. In this setting, three drugs have been approved in high-risk disease: apalutamide, enzalutamide and darolutamide.Areas covered:This manuscript aims to profile darolutamide, its clinical development, pharmacologic properties, efficacy and safety. We presented the results of published clinical studies, but we also investigated ongoing ones.Expert opinion: An indirect comparison with the other two aforementioned drugs emerged. While the clinical efficacy is comparable, the toxicity profile is different for darolutamide, resulting in greater tolerance. We must wait for the results of the trials that study darolutamide in hormone-sensitive disease, both in the metastatic phase and in the localized phase. Clinical experience will also be important to determine ever more personalized treatments for patients.

AB - Introduction: Important changes in the treatment of prostate cancer have taken place in recent years. Non-metastatic castration-resistant prostate cancer (nmCRPC) has been clinically delineated. In this setting, three drugs have been approved in high-risk disease: apalutamide, enzalutamide and darolutamide.Areas covered:This manuscript aims to profile darolutamide, its clinical development, pharmacologic properties, efficacy and safety. We presented the results of published clinical studies, but we also investigated ongoing ones.Expert opinion: An indirect comparison with the other two aforementioned drugs emerged. While the clinical efficacy is comparable, the toxicity profile is different for darolutamide, resulting in greater tolerance. We must wait for the results of the trials that study darolutamide in hormone-sensitive disease, both in the metastatic phase and in the localized phase. Clinical experience will also be important to determine ever more personalized treatments for patients.

KW - Darolutamide

KW - androgen receptor antagonist

KW - castration-resistant

KW - hormone-sensitive

KW - non-metastatic

KW - prostate cancer

UR - https://www.scopus.com/pages/publications/85102956123

U2 - 10.1080/17512433.2021.1901580

DO - 10.1080/17512433.2021.1901580

M3 - Article

C2 - 33685318

SN - 1751-2433

VL - 14

SP - 535

EP - 544

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

IS - 5

ER -

Darolutamide in hormone-sensitive and castration-resistant prostate cancer

Abstract

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this